Immix Biopharma (IMMX) Total Current Liabilities (2020 - 2026)
Immix Biopharma (IMMX) posted Total Current Liabilities of $10.5 million for Q1 2026, up 4.24% sequentially from $10.1 million in Q4 2025, and up 13.24% YoY from $9.3 million in Q1 2025.
Immix Biopharma (IMMX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Total Current Liabilities for 7 years, with the latest figure at $10.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 13.24% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 13.24% YoY) and the FY2025 annual result came in at $10.1 million, up 16.39% from the prior year.
- Total Current Liabilities improved to $10.5 million in Q1 2026 per IMMX's latest filing, from $10.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $10.9 million in Q3 2025 and troughed at $365086.0 in Q1 2022.
- A 5-year average of $5.3 million and a median of $3.9 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 530.22% in 2022, then increased 13.24% in 2026.
- Over 5 years, Total Current Liabilities stood at $1.3 million in 2022, then surged by 192.3% to $3.7 million in 2023, then surged by 133.41% to $8.7 million in 2024, then grew by 16.39% to $10.1 million in 2025, then increased by 4.24% to $10.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $10.5 million, $10.1 million, and $10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.30 Mn |
| Mar 31, 2026 | 10.54 Mn |
| Dec 31, 2025 | 10.11 Mn |
| Sep 30, 2025 | 10.85 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Mar 31, 2025 | 9.31 Mn |
| Dec 31, 2024 | 8.69 Mn |
| Sep 30, 2024 | 6.56 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 2.40 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 646,457.00 |
| Jun 30, 2022 | 977,209.00 |
| Mar 31, 2022 | 365,086.00 |
| Dec 31, 2021 | 202,039.00 |
| Dec 31, 2020 | 5.27 Mn |